All In Biotech

Drug Trial Radar · NCT07313917

A Study to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase Ⅱ Clinical Trial to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

Last checked: Nov 19, 2026Latest source record: Feb 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 150 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Jan 20, 2026

Primary completion

Feb 28, 2027

Study completion Sep 30, 2027

Sponsor

Lead sponsor
Longbio PharmaIndustry
Sponsor type
Industry
First posted
Jan 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group Phase II clinical trial. Its primary objective is to explore and preliminarily evaluate the efficacy and safety of LP-003 Injection in the treatment of participants with chronic rhinosinusitis with nasal polyps (CRSwNP), as well as to investigate its pharmacokinetic (PK), pharmacodynamic (PD) profiles, and immunogenicity.

Conditions

  • Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

Interventions

  • LP-003 InjectionBiological

    s.c. injection, Q12W

  • Placebo of LP-003Biological

    s.c. injection, Q12W

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in Nasal Polyps Score (NPS) at Week 24Time frame: Week 24
  2. Change from baseline in Nasal Congestion Score (NCS) at Week 24Time frame: Week 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Tongren Hospital Affiliated to Capital Medical University

    Beijing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.